Skip to main content

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, video visits and more. Learn More >>

Location

Texas Medical Center

Specialty
Cancer, Blood Disorders
Phone: 832-822-4242
Fax: (832) 825-1453

Address

6701 Fannin St., Ste. 1510.00
Houston, TX 77030

Jennifer H. Foster, MD, MPH

Director, Solid Tumor Programs
Clinical Director, Neuroblastoma Program
Assistant Director, Developmental Therapeutics Program
Associate Professor, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine

Education

School Education Degree Year
Baylor College of Medicine Fellowship Clinical Fellow, Pharmacology 2015
Baylor College of Medicine Fellowship Pediatric Hematology/Oncology 2013
University of Washington School of Medicine Residency Pediatrics 2010
University of Washington School of Medicine Internship Pediatrics 2009
University of Hawaii School of Medicine Medical School Doctor of Medicine 2007
San Diego State University Masters Masters in Public Health 2003
University of Notre Dame Bachelors Bachelor of Arts, Mandarin Chinese 2001

About

Dr. Jennifer Foster is a pediatric oncologist at Baylor College of Medicine/Texas Children’s Cancer and Hematology Center with clinical and research expertise in pediatric solid tumors and clinical pharmacology. She serves as Director of the Solid Tumor Programs, Clinical Director of the Neuroblastoma Program, and Assistant Director of the Developmental Therapeutics Program at Texas Children’s Cancer Center, one of the largest pediatric cancer center in the United States.

Her clinical and research interests are to bring novel therapies into early phase clinical trials for patients with neuroblastoma and other solid tumors, as well as to mitigate toxicities of therapy. As such, she is dual board certified in Pediatric Hematology-Oncology and Clinical Pharmacology. She has expertise in moving novel agents from the pre-clinical arena to the implementation of early phase clinical trials. She successfully completed the pre-clinical evaluation for the first-in-class NEDD8 activating enzyme inhibitor pevonedistat and partnered with Takeda to develop and conduct the Phase 1 clinical trial through the Children’s Oncology Group (COG).

As the site Principal Investigator for the National Cancer Institute’s Pediatric Early Phase Clinical Trials Network, she is responsible for the implementation and conduct of these trials at our institution, and is actively investigating novel agents through our Developmental Therapeutics pre-clinical program with the goal of incorporating them into future clinical trials.

Board Certifications
American Board of Pediatrics
American Board of Pediatrics - Pediatric Hematology/Oncology
American Board of Clinical Pharmacology - Clinical Pharmacology

Organizations

Organization Name Role
American Academy of Pediatrics (AAP) Member
American Medical Association (AMA) Member
American Society of Pediatric Hematology/Oncology (ASPHO) Member

Awards

2022     Dr. Peter Adamson Young Investigator Award, Children's Oncology Group (COG)
2020     Research Mentor Award, Texas Children's Hospital
2019     Faculty Award for Excellence in Patient Care, Baylor College of Medicine
2017     Awardee Rising Star in Translational Cancer Research, Society for Translational Oncology
2013     Alex’s Lemonade Stand Foundation, Research Scholar

Board Certification

American Board of Pediatrics - Pediatrics, ​​​​​​​American Board of Pediatrics - Pediatric Hematology-Oncology

Language

English

Latest Videos

Neuroblastoma Program at Texas Children’s Cancer Center®

MIBG Treatment at Texas Children’s Cancer Center

* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.